Please wait a minute...
文章检索
预防医学  2019, Vol. 31 Issue (11): 1097-1099,1104    DOI: 10.19485/j.cnki.issn2096-5087.2019.11.004
  论著 本期目录 | 过刊浏览 | 高级检索 |
EV71疫苗疑似预防接种异常反应监测结果
潘雪娇1,符剑1,沈灵智1,吕华坤1,肖艳慧2,陈海平2,石煊雯2
1.浙江省疾病预防控制中心,浙江 杭州 310051;
2.中国生物技术股份有限公司
Surveillance results of adverse events following immunization of enterovirus 71 inactvated vaccine
PAN Xue-jiao*,FU Jian,SHEN Ling-zhi,LYU Hua-kun,XIAO Yan-hui,CHEN Hai-ping,SHI Xuan-wen
*Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou,Zhejiang 310051,China
全文: PDF(1000 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 分析6月龄~3岁儿童接种武汉生物制品研究所肠道病毒71型灭活疫苗(EV71疫苗)的疑似预防接种异常反应(AEFI)发生情况,评价该疫苗的安全性。方法 按照《全国疑似预防接种异常反应监测方案》要求,采用主动监测和被动监测结合的方式收集浙江省2017年9月—2018年10月接种EV71疫苗的6月龄~3岁儿童AEFI报告病例资料,采用描述流行病学方法分析人群特征、地区分布、接种剂次及接种后发生AEFI相关情况。结果 监测接种儿童107 503人,其中主动监测27 173人,被动监测80 330人。接种EV71疫苗后发生AEFI 288例,AEFI报告发生率为267.90/10万人;其中一般反应266例,报告发生率为247.43/10万剂;异常反应14例,报告发生率为13.02/10万剂;偶合症8例,报告发生率为7.44/10万剂;无严重AEFI病例。288例AEFI病例中,被动监测145例,报告发生率为180.51/10万剂;主动监测143例,报告发生率为526.26/10万剂。男童150例,女童138例,男女比为1.09∶1。浙江省各市均有AEFI病例报告,报告病例数居前三位的是金华市、台州市和杭州市,占全省报告病例数的50.69%。接种第1剂次后发生AEFI 202例,占70.14%;AEFI在接种日发生163例,占56.60%。266例一般反应主要表现为发热、红肿和硬结;14例异常反应临床损害均较轻,其中8例为过敏性皮疹,未发现其他严重异常反应。结论 6月龄~3岁儿童接种该疫苗后AEFI报告发生率为267.90/10万剂,无严重AEFI病例,该EV71疫苗安全性良好。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
潘雪娇
符剑
沈灵智
吕华坤
肖艳慧
陈海平
石煊雯
关键词 EV71疫苗疑似预防接种异常反应监测疫苗安全性    
AbstractObjective To evaluate the safety of enterovirus 71(EV71)inactivated vaccines produced by Wuhan Institute of Bio Products through learning the incidence of adverse events following immunization(AEFI)in children aged 6 months to 3 years old after vaccination. Methods  According to the national requirement for vaccine safety monitoring program,data of AEFI cases after inoculated EV71 vaccines from September 2017 to October 2018 in Zhejiang Province was collected by combining active and passive monitoring. Demographic characteristics,space distribution,dose and incidence of AEFI were analyzed. Results A total of 107 503 children were included in this study,of which 27 173 were actively monitored and 80 330 were passively monitored. The monitoring results showed that 288 cases of AEFI occurred after inoculated EV71 vaccines,the reported incidence rate was 267.90/100 000. Of 288 cases,266 cases had common reactions(247.43/100 000),14 cases had abnormal reactions(13.02/100 000)and 8 cases had complications(7.44/100 000);145 cases were passively monitored(180.51/100 000)and 143 cases were actively monitored(526.26/100 000);150 cases were males and 138 cases were females,with the males to females ratio of 1.09∶1. The AEFI of EV71 vaccines were reported in all the cities of Zhejiang Province,with Jinhua,Taizhou and Hangzhou ranking the top three and accounting for 50.69% of all the reported cases. About 202 cases of AEFI(70.14%)occurred after the first dose of EV71 vaccines,and 163 cases(56.60%)occurred on the day of inoculation.Most of common reactions were fever,swelling and sclerosis. The harm of the reported abnormal reactions was mild,with 8 cases of anaphylactic rash and no other serious abnormal reactions were found. Conclusion The reported incidence rate of AEFI of the domestic EV71 vaccine in children aged from 6 months to 3 years is 267.90/100 000,without serious abnormal reactions,suggesting that the EV71 vaccine is safe.
Key wordsEnterovirus 71 inactivated vaccine    Adverse events following immunization    Surveillance    Vaccine safety
          出版日期: 2019-11-01
中图分类号:  R186  
基金资助:浙江省医药卫生科技项目(2019KY053)
通信作者: 符剑,E-mail:jfu@cdc.zj.cn   
作者简介: 潘雪娇,硕士,主管医师,主要从事疫苗接种及安全性研究工作
引用本文:   
潘雪娇, 符剑, 沈灵智, 吕华坤, 肖艳慧, 陈海平, 石煊雯. EV71疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2019, 31(11): 1097-1099,1104.
PAN Xue-jiao, FU Jian, SHEN Ling-zhi, LYU Hua-kun, XIAO Yan-hui, CHEN Hai-ping, SHI Xuan-wen. Surveillance results of adverse events following immunization of enterovirus 71 inactvated vaccine. Preventive Medicine, 2019, 31(11): 1097-1099,1104.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2019.11.004      或      http://www.zjyfyxzz.com/CN/Y2019/V31/I11/1097
[1] 中华人民共和国国家卫生健康委员会.2017年全国法定传染病疫情概况[EB/OL].(2018-02-26) [2019-08-17]. http:// www.nhc.gov.cn/jkj/s3578/201802/de926bdb046749abb7b0a8e23d 929104.shtml.
[2] 吴晨,吴昊澄,丁哲渊,等.2008—2015年浙江省手足口病流行特征分析[J].疾病监测,2016,31(10):831-834.
[3] LI R,LIU L,MO Z,et al.An inactivated enterovirus 71 vaccine in healthy children[J].N Engl J Med,2014,370(9):829- 837.
[4] ZHU F,XU W,XIA J,et al.Efficacy,safety,and immunogenicity of an enterovirus 71 vaccine in China[J].N Engl J Med,2014,370(9):818-828.
[5] HU Y M,WANG X,WANG J Z,et al.Immunogenicity,safety,and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months[J].Clin Vaccine Immunol,2013,(12):1805-1811.
[6] 中华人民共和国卫生部,国家食品药品监督管理局.全国疑似预防接种异常反应监测方案[S].2010.
[7] 白云骅,李丽,张军楠,等.肠道病毒71型灭活疫苗上市后安全性主动监测[J].中国公共卫生,2017,33(4):65-67.
[8] 杜进发,钟革,陆伟才,等.2016—2017年广西肠道病毒71型灭活疫苗疑似预防接种异常反应监测结果分析[J].应用预防医学,2018,24(5):384-386.
[9] 汪志国,汤奋扬,高君,等.肠道病毒71型灭活疫苗上市后安全性监测与评价[J].江苏预防医学,2018,29(6):626- 629.
[10]辛秀梅,张金凤,热孜万,等.新疆疑似预防接种异常反应主动监测项目结果分析[J].中国妇幼保健,2012,27(24):3747-3749.
[11]沈金花,陆红梅,黄卓英,等.上海市松江区乙型肝炎疫苗安全性主动与被动监测[J].职业与健康,2012,28(24):3125-3127.
[12]王亚丽,董锋,王丹,等.美国疫苗上市后安全性监测给我们的启示[J].中国药事,2015,29(9):908-911.
[13]黄巍,周晓红,席胜,等.两种EV71型灭活疫苗安全性比较[J].预防医学,2018,30(4):356-358.
[14]刘世科,陈伟,王帆,等.婴幼儿接种EV71疫苗的安全性观察[J].预防医学,2019,31(5):505-507.
[15]戚小华,李倩,凌罗亚,等.浙江省2010—2012年麻疹成分疫苗疑似预防接种异常反应监测分析[J].国际流行病学传染病学杂志,2013,40(5):317-320.
[16]孙肖瑜,魏晶娇,李万仓,等.温州市EV71灭活疫苗的疑似预防接种异常反应分析[J].预防医学,2018,30(6):629- 630.
[1] 张超, 罗小福, 刘艳, 沈建勇, 徐秦儿, 韩利萍, 马力. 湖州市老年人接种流感灭活疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(8): 701-704.
[2] 马艳艳, 陈小劲, 赵月. 朝阳区3~6岁儿童体质健康调查[J]. 预防医学, 2023, 35(7): 615-619.
[3] 徐杰, 陈棕棕, 骆水娟, 李欢龙. 富阳区市售食品食源性致病菌监测结果[J]. 预防医学, 2023, 35(7): 624-627.
[4] 潘晓东, 韩见龙, 陈苘. 鸡肉中多种抗生素超高效液相-静电场轨道阱高分辨质谱检测方法[J]. 预防医学, 2023, 35(5): 456-459.
[5] 钱晓萍, 罗小福, 凌健. 湖州市疫苗接种相关的过敏性皮疹监测结果[J]. 预防医学, 2023, 35(4): 339-341.
[6] 赵冲, 施文文. 富阳区监测哨点医院急诊就诊伤害病例特征分析[J]. 预防医学, 2023, 35(2): 155-157,161.
[7] 江伟, 刘艳, 杜渐, 许玉洋, 车鑫仁, 王婧, 王骏, 张学潮, 顾雯雯, 张小平. 2017—2021年杭州市HPV疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(1): 71-73,77.
[8] 张超, 沈建勇, 罗小福, 徐秦儿, 韩利萍. 2015—2021年湖州市MMR疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(1): 74-77.
[9] 刘迎男, 杨景元, 李慧, 杨虹, 杲柏呈, 高雅, 李向春, 曹猛. 2013—2021年内蒙古自治区五类重点人群丙型肝炎监测结果[J]. 预防医学, 2022, 34(9): 941-945.
[10] 傅天颖, 吴昊澄, 鲁琴宝, 丁哲渊, 王心怡, 杨珂, 吴晨, 林君芬. 2021年浙江省法定传染病疫情分析[J]. 预防医学, 2022, 34(8): 842-847.
[11] 林君芬. 浙江省防范输入性猴痘疫情的对策建议[J]. 预防医学, 2022, 34(8): 757-759.
[12] 王晓柳, 汤元妃. 2018—2021年武义县疑似预防接种异常反应监测结果[J]. 预防医学, 2022, 34(11): 1167-1171,1177.
[13] 韩东方, 俞丹丹, 李晨晨, 袁佳春, 叶玉龙, 阙凤霞. 2014—2020年金山区食源性疾病监测结果[J]. 预防医学, 2022, 34(1): 91-94.
[14] 刘静, 徐沛维, 陈志健, 邵斌, 施长苗, 李胜, 王晓峰. 人群邻苯二甲酸酯暴露水平研究综述[J]. 预防医学, 2021, 33(9): 906-909,912.
[15] 郭佳娣, 郦依华, 俞顺飞, 赖忠俊, 郝小吉, 胡桂佳, 赵尧贤, 宣志强. 2011—2019年浙江省11家省级医院放射工作人员外照射个人剂量监测结果分析[J]. 预防医学, 2021, 33(9): 948-950.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed